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A potent tumor-specific T cell response is an important
part of antitumor immunity. Thus, enhancing T cell
responses against tumor cells is a major focus in cancer
immunotherapy. Dendritic cells (DC) play a critical role
in the induction of T cell responses not only against
pathogens but also against tumor cells. Studies have
shown that DC-based vaccines are capable of presenting
antigens via MHC Class I and MHC Class II molecules
resulting in tumor antigen-specific T cell activation in
vitro and in vivo. However, T cell responses against
tumor antigens can be negatively regulated. For exam-
ple, PD-1, which is up-regulated in activated T cells, can
bind to PD-L1 or PD-L2 expressed in tumor cells as
part of the immune suppressive tumor environment and
thus inhibiting T cell activation. We wished to deter-
mine whether addition of anti-PD-1 to DC vaccines
would result in enhanced tumor antigen-specific T cell
responses. DCs transduced with recombinant adenovirus
(AdV) encoding anti-PD1 (Ad5.hPD1Ab) secreted anti-
PD1 in the supernatants which was able to bind to PD-
1 expressed on the surface of HEK-293 cells via stable
transfection. We examined the expression of surface
markers associated with DC function and maturation 48
hours after transduction via flow cytometry. Our results
show that Ad5.hPD1Ab transduced DCs had similar
expression levels of antigen presentation molecules
MHC Class I and II, costimulatory, and maturation
related molecules CD40, CD80, CD83 and CD86 com-
pared to DCs that were transduced with adenovirus
encoding tumor antigens for hepatocellular carcinoma
and melanoma (AdVhAFP and AdVTMM2, respectively).
Furthermore, surface expression of inhibitory molecules
PD-L1 and PD-L2 were also comparable among the three
groups. Cytokine analysis show that 24-48 hours after
transduction, Ad5.hPD1Ab transduced DCs secrete more
IL-7, IL-15 and IP-10 than AdVhAFP and AdVTMM2
transduced DCs. Importantly, autologous T cells co-
cultured with Ad5.hPD1Ab transduced DC results in
reduced expression of not only surface PD-1 but also
surface CTLA-4 inhibitory molecules in both CD4+
and CD8+ T cells.
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